Education
About Us
Working with TipRanks
Follow Us
Xspray Pharma AB (DE:6XP)
:6XP
6XP Stock Chart & Stats
Day’s Range― - ―
52-Week Range€2.10 - €7.67
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€80.37M
Enterprise Value€1.36B
Total Cash (Recent Filing)kr192.85M
Total Debt (Recent Filing)kr8.28M
Price to Earnings (P/E)―
Beta1.08
Next Earnings
May 07, 2025EPS Estimate
-0.16Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.74
Shares Outstanding30,872,599
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)5562.19
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
---
Options Prices
Currently, No data available
---
Ownership Overview
―
Insiders
―
Mutual Funds
― Other Institutional Investors
99.97% Public Companies and
Individual Investors
6XP FAQ
What was Xspray Pharma AB’s price range in the past 12 months?
Xspray Pharma AB lowest stock price was €2.10 and its highest was €7.67 in the past 12 months.
What is Xspray Pharma AB’s market cap?
Xspray Pharma AB’s market cap is €80.37M.
When is Xspray Pharma AB’s upcoming earnings report date?
Xspray Pharma AB’s upcoming earnings report date is May 07, 2025 which is in 26 days.
How were Xspray Pharma AB’s earnings last quarter?
Xspray Pharma AB released its earnings results on Feb 12, 2025. The company reported -€0.166 earnings per share for the quarter, the consensus estimate of -€0.166 by €0.
Is Xspray Pharma AB overvalued?
According to Wall Street analysts Xspray Pharma AB’s price is currently Overvalued.
Does Xspray Pharma AB pay dividends?
Xspray Pharma AB does not currently pay dividends.
What is Xspray Pharma AB’s EPS estimate?
Xspray Pharma AB’s EPS estimate is -0.16.
How many shares outstanding does Xspray Pharma AB have?
Xspray Pharma AB has 30,872,599 shares outstanding.
What happened to Xspray Pharma AB’s price movement after its last earnings report?
Xspray Pharma AB reported an EPS of -€0.166 in its last earnings report, expectations of -€0.166. Following the earnings report the stock price went up 2.899%.
Which hedge fund is a major shareholder of Xspray Pharma AB?
Currently, no hedge funds are holding shares in DE:6XP
---
Company Description
Xspray Pharma AB
XSpray Pharma AB is a product development company with several product candidates in clinical development. It develops, sells and licenses generic versions of marketed cancer drugs, protein kinase inhibitors. The company primarily develops protein kinase inhibitors (PKI) for targeted cancer treatment.
---
Technical Analysis
SynAct Pharma AB
―
Saniona AB
―
Xbrane Biopharma AB
―
IRLAB Therapeutics AB Class A
―
Cantargia AB
―
---